{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:04:13Z","timestamp":1772463853560,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Applied Sciences"],"abstract":"<jats:p>Breast cancer was responsible for the deaths of 626,679 women in 2018. After decades of research, the mortality rates remain high. While the barrier of selectively killing tumor cells is not yet overcome, the search for targeted therapeutics continues. The use of nanomedicine in cancer treatment has opened up new possibilities for more precise drug-delivery systems. This review aimed to gather information and analyze recent clinical trials evaluating the therapeutic effects of nanoparticles in the treatment of metastatic breast cancer. To accomplish this, the clinicaltrials.gov database was consulted, and after employing specific exclusion criteria, 11 clinical trials were selected. Nanoparticle albumin-stabilized paclitaxel was evaluated in ten clinical trials and paclitaxel-incorporating polymeric micelles were assessed in one clinical trial. Overall, this review confirmed a clinical benefit in the use of nanoparticle albumin-stabilized paclitaxel for the treatment of breast cancer, with reduced toxicity when compared to first-line treatments. Three studies did not meet the primary endpoint, however, and so the authors advised further evaluations. Although the use of nanomedicine is revolutionizing the cancer field, to integrate this regimen into generalized clinical treatment, additional clinical trials must be performed to achieve a favorable safety and efficacy profile.<\/jats:p>","DOI":"10.3390\/app11041624","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T17:20:38Z","timestamp":1613150438000},"page":"1624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer"],"prefix":"10.3390","volume":"11","author":[{"given":"Rita","family":"Moreira","sequence":"first","affiliation":[{"name":"Faculdade de Medicina e Ci\u00eancias Biom\u00e9dicas, Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal"},{"name":"ABC-RI, Algarve Biomedical Center Research Institute, 8005-139 Faro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-8190","authenticated-orcid":false,"given":"Andreia","family":"Granja","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-1355","authenticated-orcid":false,"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-2835","authenticated-orcid":false,"given":"Salette","family":"Reis","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1038\/527S101a","article-title":"Breast cancer","volume":"527","author":"Woolston","year":"2015","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_3","unstructured":"World Health Organization (2014). World Cancer Report 2014, World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"c3620","DOI":"10.1136\/bmj.c3620","article-title":"Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database","volume":"341","author":"Autier","year":"2010","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy. Angew","volume":"53","author":"Sun","year":"2014","journal-title":"Chem. Int. Ed. Engl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: Mechanistic insights and clinical challenges","volume":"12","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) dagger","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3892\/or_00000963","article-title":"Chemotherapy for breast cancer (Review)","volume":"24","author":"Hassan","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.molonc.2016.07.002","article-title":"Metastatic breast cancer: The Odyssey of personalization","volume":"10","author":"Sonnenblick","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00615-4","article-title":"Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles","volume":"18","author":"Unal","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/1389200220666191016124958","article-title":"Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Diagnosis and Treatment of Breast, Ovarian and Cervical Cancers","volume":"20","author":"Talluri","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jso.25747","article-title":"Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe","volume":"120","author":"Taruno","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Harpern, S.H., and Douglas, M.J. (2005). Jadad scale for reporting randomized controlled trials. Evid. Based Obstet. Anesth., 237.","DOI":"10.1002\/9780470988343.app1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10549-011-1411-8","article-title":"Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib","volume":"132","author":"Kaklamani","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","unstructured":"(2020, December 29). ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT00856492, S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00856492."},{"key":"ref_20","unstructured":"(2020, December 29). ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT00733408, Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00733408."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-012-2341-9","article-title":"Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen","volume":"137","author":"Yardley","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clbc.2014.02.005","article-title":"Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer","volume":"14","author":"Mrozek","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/jco.2011.29.15_suppl.1126","article-title":"Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735","volume":"29","author":"Northfelt","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.clbc.2013.08.003","article-title":"Nab-Paclitaxel\/Bevacizumab\/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer","volume":"13","author":"Hamilton","year":"2013","journal-title":"Clin. Breast Cancer"},{"key":"ref_25","unstructured":"(2020, December 29). ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT00407888, Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00407888."},{"key":"ref_26","unstructured":"(2020, December 29). ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT00254592, Neoadjuvant Treatment of Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00254592."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CBC.2010.n.036","article-title":"Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer","volume":"10","author":"Conlin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","article-title":"Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2\u2013Overexpressing Metastatic Breast Cancer","volume":"31","author":"Guan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000318043","article-title":"A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer","volume":"79","author":"Tjulandin","year":"2010","journal-title":"Oncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel","volume":"92","author":"Hamaguchi","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/1061186X.2014.958844","article-title":"Nanoparticulate carriers: An emerging tool for breast cancer therapy","volume":"23","author":"Tharkar","year":"2014","journal-title":"J. Drug Target."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.2147\/IJN.S140325","article-title":"Drug delivery approaches for breast cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_34","first-page":"419","article-title":"Nanoparticle-mediated targeted drug delivery for breast cancer treatment","volume":"1871","author":"Liyanage","year":"2019","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2009.21.8594","article-title":"Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer","volume":"28","author":"Boussen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yan, L., Shen, J., Wang, J., Yang, X., Dong, S., and Lu, S. (2020). Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology. Dose-Response, 18.","DOI":"10.1177\/1559325820936161"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2011.03.019","article-title":"A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer","volume":"11","author":"Brufsky","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3816\/CBC.2005.n.047","article-title":"Two Concurrent Phase II Trials of Paclitaxel\/Carboplatin\/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252","volume":"6","author":"Perez","year":"2005","journal-title":"Clin. Breast Cancer"}],"container-title":["Applied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3417\/11\/4\/1624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:54Z","timestamp":1760160174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3417\/11\/4\/1624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["app11041624"],"URL":"https:\/\/doi.org\/10.3390\/app11041624","relation":{},"ISSN":["2076-3417"],"issn-type":[{"value":"2076-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}